Developing new drugs is expensive and time-consuming, yet, digital manufacturing techniques are delivering significant benefits without compromising on quality, as Eric Flynn, Head of Pharmaceuticals and Life Sciences at Siemens GB&I explains.
Albina Pace from Emerson explains how digitalisation and software solutions are enabling manufacturers to perform faster technology transfers and make their operations leaner, helping them to achieve pipeline acceleration.
Ori Biotech’s Chief Digital Officer Kevin Gordon discusses the key pain points that are preventing patients from accessing this new generation of curative therapies.
Editor, Rebekah Jordan, reviews pharma's transformation to digital solutions, and how the industry will need to navigate the associated risks to prevent breaches in security and safety.
EPM's Q&A with Jack Dix, head of healthcare strategy and consulting at Kainos, examines technology in genomics research and how cloud data transformation can help to build better patient outcomes.
Nearly half of senior decision-makers working for drug development companies or manufacturers said data silos derailed the efficiency of cross-functional collaboration in their organisation.
As the life sciences sector grapples with a rapidly changing environment and increasing regulatory scrutiny, Frits Stulp of Iperion – a Deloitte business, predicts that harnessing the power of digital transformation can optimise patient outcomes.
Michael Earl, director, pharmaceutical services at Owen Mumford, examines the benefits that patients are set to receive as the connected drug delivery devices market grows.
Christian Marcazzo, vice president/general manager of IDBS discusses how cloud-based solutions can create seamless communication between innovators and CDMOs.
Simon Tilley, SAS, breaks down the benefits and drawbacks of decentralised clinical trials (DCT). He also explains how AI, machine learning and advanced analytics can refine all stages from participant recruitment to compiling results.
Rebekah Jordan sat with Kelly Doering, AspenTech, to learn more about how digitalisation in pharma manufacturing is key to overcoming drug shortages such as this one, and how the industry can build a more resilient and flexible supply chain.
Deloitte’s Patrick Middag and Dennie van de Voort provide some practical steps to creating and entrenching effective data governance practices which in turn can help elevate the quality and value of regulated pharma data.
